Metabolomic Signatures and Machine Learning Models for Distinguishing Alzheimer's Disease and Dementia with Lewy Bodies

This study demonstrates the potential of metabolomic biomarkers in differentiating AD from DLB, with APOE improving classification accuracy for AD. Future efforts will focus on validating findings in larger cohorts and translating these findings into non-invasive, cost-effective tool set to reduce AD and DLB misdiagnosis.